Centessa PharmaceuticalsCNTA
About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Employees: 75
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
256% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 9
175% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 16
116% more capital invested
Capital invested by funds: $804M [Q2] → $1.74B (+$936M) [Q3]
29% more funds holding
Funds holding: 80 [Q2] → 103 (+23) [Q3]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
5.81% more ownership
Funds ownership: 78.75% [Q2] → 84.55% (+5.81%) [Q3]
88% less call options, than puts
Call options by funds: $99K | Put options by funds: $848K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Guggenheim Debjit Chattopadhyay 35% 1-year accuracy 7 / 20 met price target | 62%upside $28 | Buy Maintained | 15 Nov 2024 |